Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,956 questions in 143 reviews · Musculoskeletal

current versions

No studies 555 · 28.4%Ungraded 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + MTX/DMARD DAS Remission defined as DAS28 <2.6 · patients with rheumatoid arthritis Tocilizumab for rheumatoid arthritis (2010) · Cochrane	RR 8.74 [6.26, 11.8]	4 studies · 1946 participants	High
Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + MTX/DMARD HAQ improvement of >0.3 or MHAQ decrease of >0.22 (changes exceeding MCID) · patients with rheumatoid arthritis Tocilizumab for rheumatoid arthritis (2010) · Cochrane	RR 1.79 [1.62, 1.94]	1 study · 1220 participants	High
Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + MTX/DMARD Serious Adverse Events · patients with rheumatoid arthritis Tocilizumab for rheumatoid arthritis (2010) · Cochrane	RR 1.17 [0.83, 1.64]	3 studies · 1961 participants	Moderate
Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + MTX/DMARD Total withdrawals · patients with rheumatoid arthritis Tocilizumab for rheumatoid arthritis (2010) · Cochrane	RR 0.61 [0.49, 0.77]	4 studies · 2064 participants	Moderate
Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + MTX/DMARD Withdrawals due to Adverse events · patients with rheumatoid arthritis Tocilizumab for rheumatoid arthritis (2010) · Cochrane	RR 1.43 [0.95, 2.12]	4 studies · 2064 participants	High
Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + MTX/DMARD Radiographic Progression · patients with rheumatoid arthritis Tocilizumab for rheumatoid arthritis (2010) · Cochrane	no estimate extracted	0 studies · 4 participants	Ungraded
Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX ACR50 · patients with rheumatoid arthritis Golimumab for rheumatoid arthritis (2010) · Cochrane	RR 2.57 [1.34, 4.94]	4 studies · 919 participants	High
Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX Disease activity (DAS Remission) · patients with rheumatoid arthritis Golimumab for rheumatoid arthritis (2010) · Cochrane	RR 5.12 [1.67, 15.66]	4 studies · 919 participants	High
Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX Physical function ‐ HAQ Score points. Scale from: 0 to 3. · patients with rheumatoid arthritis Golimumab for rheumatoid arthritis (2010) · Cochrane	no estimate extracted	1 study · 308 participants	High
Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX Adverse Events · patients with rheumatoid arthritis Golimumab for rheumatoid arthritis (2010) · Cochrane	RR 1.05 [0.93, 1.18]	4 studies · 918 participants	High
Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX Serious Adverse Events · patients with rheumatoid arthritis Golimumab for rheumatoid arthritis (2010) · Cochrane	RR 1.05 [0.62, 1.78]	4 studies · 918 participants	High
Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX All Withdrawals · patients with rheumatoid arthritis Golimumab for rheumatoid arthritis (2010) · Cochrane	RR 0.5 [0.31, 0.81]	4 studies · 917 participants	High
Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX Withdrawals due to Adverse Events · patients with rheumatoid arthritis Golimumab for rheumatoid arthritis (2010) · Cochrane	RR 0.56 [0.24, 1.29]	3 studies · 599 participants	High
MTX combination vs MTX monotherapy ACR 50 response of DMARDs naive patients Number of responders · patients with Rheumatoid arthritis Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying… (2010) · Cochrane	RR 1.76 [0.64, 4.85]	2 studies · 127 participants	Low
MTX combination vs MTX monotherapy ACR 50 response of MTX inadequate responders number of responders · patients with Rheumatoid arthritis Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying… (2010) · Cochrane	RR 4.54 [2.51, 8.2]	3 studies · 404 participants	Moderate
MTX combination vs MTX monotherapy ACR 50 response of non‐MTX DMARDs inadequate responders number of responders · patients with Rheumatoid arthritis Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying… (2010) · Cochrane	RR 1.68 [0.94, 2.99]	2 studies · 158 participants	Moderate
MTX combination vs MTX monotherapy Withdrawal due to lack of efficacy or toxicity of DMARDs naive patients number of withdrawals · patients with Rheumatoid arthritis Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying… (2010) · Cochrane	RR 1.16 [0.7, 1.93]	5 studies · 405 participants	Moderate
MTX combination vs MTX monotherapy Withdrawal due to lack of efficacy or toxicity of MTX inadequate responders number of withdrawals · patients with Rheumatoid arthritis Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying… (2010) · Cochrane	RR 0.86 [0.49, 1.51]	3 studies · 476 participants	Moderate
MTX combination vs MTX monotherapy Withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs inadequate responders number of withdrawals · patients with Rheumatoid arthritis Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying… (2010) · Cochrane	RR 0.75 [0.41, 1.35]	5 studies · 329 participants	Very low
MTX combination vs MTX monotherapy Withdrawal due to adverse reactions (Pooled across regimens) number of withdrawals · patients with Rheumatoid arthritis Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying… (2010) · Cochrane	RR 1.59 [1.2, 2.12]	17 studies · 1624 participants	Very low
Intervention NR Pain Various pain scales Median · patients with osteoarthritis Transcutaneous electrostimulation for osteoarthritis of the knee (2009) · Cochrane	no estimate extracted	16 studies · 726 participants	Very low
Intervention NR Function Various validated function scales Median · patients with osteoarthritis Transcutaneous electrostimulation for osteoarthritis of the knee (2009) · Cochrane	no estimate extracted	9 studies · 407 participants	Very low
Intervention NR Number of patients experiencing any adverse event Median · patients with osteoarthritis Transcutaneous electrostimulation for osteoarthritis of the knee (2009) · Cochrane	RR 1.02 [0.53, 1.97]	3 studies · 175 participants	Low
Intervention NR Number of patients withdrawn or dropped out because of adverse events Median · patients with osteoarthritis Transcutaneous electrostimulation for osteoarthritis of the knee (2009) · Cochrane	RR 0.97 [0.16, 6]	8 studies · 363 participants	Moderate
Intervention NR Number of patients experiencing any serious adverse event Median follow ‐up: 4 weeks · patients with osteoarthritis Transcutaneous electrostimulation for osteoarthritis of the knee (2009) · Cochrane	RR 0.33 [0.02, 7.32]	4 studies · 195 participants	Low
Summary of findings: 5 mg/day vs placebo Benefits · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation Function ‐ not measured · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation Harms · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation Headache ( · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	RR 1.73 [0.92, 3.24]	1 study · 53 participants	Low
Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation Rash ( · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	RR 3.12 [0.35, 28.06]	1 study · 53 participants	Low
Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic Benefits · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic Pain ‐ not reported1 · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic Function ‐ not measured · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic Harms · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic Headache ( · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	RR 31.003 [1.96, 490.31]	1 study · 48 participants	Very low
Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic Injection site pain ( · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	RR 0.11 [0.01, 1.96]	1 study · 48 participants	Very low
Summary of findings: 5 mg/day vs placebo Adjusted pain intensity Visual Analog Scale. Scale from: 0 to 10. ( · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	1 study · 20 participants	Low
Summary of findings: 5 mg/day vs placebo Symptom free ( · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	RR 1.91 [1.04, 3.5]	1 study · 20 participants	Very low
Summary of findings: 5 mg/day vs placebo Function ‐ not measured · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 5 mg/day vs placebo Harms · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 5 mg/day vs placebo Headache ‐ not reported4 · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation Benefits · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation Pain ‐ not reported1 · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	no estimate extracted	NR	No studies
Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation Symptom free with activities of daily living (patient rated) ( · People with rotator cuff disease Topical glyceryl trinitrate for rotator cuff disease (2009) · Cochrane	RR 1.92 [0.92, 4.1]	1 study · 57 participants	Low
Eye drop dispenser device vs standard bottle Difficulty squeezing out drops · patients with rheumatoid arthritis Assistive technology for rheumatoid arthritis (2009) · Cochrane	RR 0.22 [0.06, 0.62]	1 study · 58 participants	Low
Eye drop dispenser device vs standard bottle Difficulty getting drops into eyes · patients with rheumatoid arthritis Assistive technology for rheumatoid arthritis (2009) · Cochrane	RR 0.27 [0.1, 0.71]	1 study · 58 participants	Low
Eye drop dispenser device vs standard bottle Difficulty squeezing bottle · patients with rheumatoid arthritis Assistive technology for rheumatoid arthritis (2009) · Cochrane	RR 0.56 [0.31, 0.99]	1 study · 58 participants	Low
Eye drop dispenser device vs standard bottle Difficulty controlling the number of drops · patients with rheumatoid arthritis Assistive technology for rheumatoid arthritis (2009) · Cochrane	RR 0.61 [0.37, 1]	1 study · 50 participants	Low
Eye drop dispenser device vs standard bottle Difficulty aiming drops · patients with rheumatoid arthritis Assistive technology for rheumatoid arthritis (2009) · Cochrane	RR 0.6 [0.37, 0.98]	1 study · 49 participants	Low
Eye drop dispenser device vs standard bottle Device usability · patients with rheumatoid arthritis Assistive technology for rheumatoid arthritis (2009) · Cochrane	no estimate extracted	1 study · 58 participants	Ungraded